Correction: Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours (Nature Communications (2014) 5 (4802) DOI: 10.1038/ncomms5802);Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours

Nature Communications

Volumn 2, Issue , 2014, Pages

  Rakheja, Dinesh ^a,b,c   Chen, Kenneth S ^a,b,d   Liu, Yangjian ^d   Shukla, Abhay A ^a,d   Schmid, Vanessa ^d   Chang, Tsung Cheng ^d   Khokhar, Shama ^b   Wickiser, Jonathan E ^a,b   Karandikar, Nitin J ^a   Malter, James S ^a   Mendell, Joshua T ^a,d   Amatruda, James F ^a,b,c,d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b CHILDREN S MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICER; MICRORNA; PROTEIN; PROTEIN DICER1; PROTEIN DROSHA; PROTEIN LET 7; PROTEIN LIN28; PROTEIN MYCN; RIBONUCLEASE III; RIBONUCLEASE IIIB; UNCLASSIFIED DRUG; DEAD BOX PROTEIN; DICER1 PROTEIN, HUMAN; DROSHA PROTEIN, HUMAN;

CANCER; GENE EXPRESSION; GENETIC ANALYSIS; MUTATION; RNA; TUMOR;

ARTICLE; BIOGENESIS; CANCER SUSCEPTIBILITY; CHILD; CLINICAL ARTICLE; FEMALE; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE SEQUENCE; GENOTYPE; HAPLOINSUFFICIENCY; HCT116 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFANT; MALE; MISSENSE MUTATION; NEPHROBLASTOMA; PRESCHOOL CHILD; RNA PROCESSING; SOMATIC MUTATION; COHORT ANALYSIS; DNA SEQUENCE; GENETICS; HEK293 CELL LINE; KIDNEY TUMOR; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DEAD-BOX RNA HELICASES; FEMALE; HEK293 CELLS; HUMANS; INFANT; KIDNEY NEOPLASMS; MALE; MICRORNAS; MUTATION, MISSENSE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBONUCLEASE III; SEQUENCE ANALYSIS, DNA; WILMS TUMOR;

EID: 84922792031     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms16177     Document Type: Erratum

References (54)

1. Chu, A. et al. Wilms' tumour: a systematic review of risk factors and meta-analysis. Paediatr. Perinat. Epidemiol. 24, 449-469 (2010).
2. Rivera, M. N. & Haber, D. A. Wilms' tumour: connecting tumorigenesis and organ development in the kidney. Nat. Rev. Cancer 5, 699-712 (2005).
3. Ko, E. Y. & Ritchey, M. L. Current management of Wilms' tumor in children. J. Pediatr. Urol. 5, 56-65 (2009).
4. Kalapurakal, J. A. et al. Management of Wilms' tumour: current practice and future goals. Lancet Oncol. 5, 37-46 (2004).
5. Murphy, W. M., Grignon, D. J. & Perlman, E. J. in AFIP Atlas of Tumor Pathology Series 4. Tumors of the Kidney, Bladder, and Related Urinary Structures (ed. Silverberg, S. G.) (American Registry of Pathology, 2004).
6. Robison, L. L. The Childhood Cancer Survivor Study: a resource for research of long-term outcomes among adult survivors of childhood cancer. Minn. Med. 88, 45-49 (2005).
7. Wright, K. D., Green, D. M. & Daw, N. C. Late effects of treatment for Wilms tumor. Pediatr. Hematol. Oncol. 26, 407-413 (2009).
8. Geenen, M. M. et al. Medical assessment of adverse health outcomes in longterm survivors of childhood cancer. JAMA 297, 2705-2715 (2007).
9. Sasso, G., Greco, N., Murino, P. & Sasso, F. S. Late toxicity in Wilms tumor patients treated with radiotherapy at 15 years of median follow-up. J. Pediatr. Hematol. Oncol. 32, e264-e267 (2010).
10. Ruteshouser, E. C., Robinson, S. M. & Huff, V. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosomes Cancer 47, 461-470 (2008).
11. Foulkes, W. D. et al. Extending the phenotypes associated with DICER1 mutations. Hum. Mutat. 32, 1381-1384 (2011).
12. Slade, I. et al. DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J. Med. Genet. 48, 273-278 (2011).
13. Klein, S. et al. Expanding the phenotype of mutations in DICER1: mosaic missense mutations in the RNase IIIb domain of DICER1 cause GLOW syndrome. J. Med. Genet. 51, 294-302 (2014).
14. Wu, M. K. et al. Biallelic DICER1 mutations occur in Wilms tumours. J. Pathol. 230, 154-164 (2013).
15. Torrezan, G. T. et al. Recurrent somatic mutation in DROSHA induces microRNA profile changes in Wilms tumour. Nat. Commun. 5, 4039 (2014).
16. Lee, R. S. et al. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J. Clin. Invest. 122, 2983-2988 (2012).
17. Schwartzentruber, J. et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482, 226-231 (2012).
18. Hasselblatt, M. et al. Nonsense mutation and inactivation of SMARCA4 (BRG1) in an atypical teratoid/rhabdoid tumor showing retained SMARCB1 (INI1) expression. Am. J. Surg. Pathol. 35, 933-935 (2011).
19. Pugh, T. J. et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488, 106-110 (2012).
20. Robinson, G. et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 488, 43-48 (2012).
21. Sausen, M. et al. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat. Genet. 45, 12-17 (2013).
22. Pugh, T. J. et al. The genetic landscape of high-risk neuroblastoma. Nat. Genet. 45, 279-284 (2013).
23. Nisen, P. D., Zimmerman, K. A., Cotter, S. V., Gilbert, F. & Alt, F. W. Enhanced expression of the N-myc gene in Wilms' tumors. Cancer Res. 46, 6217-6222 (1986).
24. Williams, R. D. et al. Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor. Genes Chromosome Cancer 50, 982-995 (2011).
25. Williams, R. D. et al. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. Clin. Cancer Res. 16, 2036-2045 (2010).
26. Krol, J., Loedige, I. & Filipowicz, W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 11, 597-610 (2010).
27. Lee, Y. et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 425, 415-419 (2003).
28. Gurtan, A. M., Lu, V., Bhutkar, A. & Sharp, P. A. In vivo structure-function analysis of human Dicer reveals directional processing of precursor miRNAs. RNA 18, 1116-1122 (2012).
29. Han, J. et al. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 18, 3016-3027 (2004).
30. Blaszczyk, J. et al. Crystallographic and modeling studies of RNase III suggest a mechanism for double-stranded RNA cleavage. Structure 9, 1225-1236 (2001).
31. Zhang, H., Kolb, F. A., Jaskiewicz, L., Westhof, E. & Filipowicz, W. Single processing center models for human Dicer and bacterial RNase III. Cell 118, 57-68 (2004).
32. Heravi-Moussavi, A. et al. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. New Engl. J. Med. 366, 234-242 (2012).
33. Anglesio, M. et al. Cancer-associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse strand expression bias to predominantly mature 3p strands through loss of 5p strand cleavage. J. Pathol. 229, 400-409 (2013).
34. Macrae, I. J. et al. Structural basis for double-stranded RNA processing by Dicer. Science 311, 195-198 (2006).
35. Bussing, I., Slack, F. J. & Grosshans, H. let-7 microRNAs in development, stem cells and cancer. Trends Mol. Med. 14, 400-409 (2008).
36. Pugh, T. J. et al. Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences. Oncogene doi:101038/onc.2014.150 (2014).
37. Seki, M. et al. Biallelic DICER1 Mutations in Sporadic Pleuropulmonary Blastoma. Cancer Res. 74, 2742-2749 (2014).
38. Kumar, M. S. et al. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev. 23, 2700-2704 (2009).
39. Lambertz, I. et al. Monoallelic but not biallelic loss of Dicer1 promotes tumorigenesis in vivo. Cell Death Differ. 17, 633-641 (2010).
40. Bahubeshi, A., Tischkowitz, M. & Foulkes, W. D. miRNA processing and human cancer: DICER1 cuts the mustard. Sci. Transl. Med. 3, 111ps146 (2011).
41. Hill, D. A. et al. DICER1 mutations in familial pleuropulmonary blastoma. Science 325, 965 (2009).
42. Sabbaghian, N. et al. Germline DICER1 mutation and associated loss of heterozygosity in a pineoblastoma. J. Med. Genet. 49, 417-419 (2012).
43. Francia, S. et al. Site-specific DICER and DROSHA RNA products control the DNA-damage response. Nature 488, 231-235 (2012).
44. Viswanathan, S. R. et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat. Genet. 41, 843-848 (2009).
45. West, J. A. et al. A role for Lin28 in primordial germ-cell development and germ-cell malignancy. Nature 460, 909-913 (2009).
46. Molenaar, J. J. et al. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat. Genet. 44, 1199-1206 (2012).
47. Chang, T. C. et al. Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc. Natl Acad. Sci. USA 106, 3384-3389 (2009).
48. Urbach, A. et al. Lin28 sustains early renal progenitors and induces Wilms tumor. Genes Dev. 28, 971-982 (2014).
49. Landthaler, M., Yalcin, A. & Tuschl, T. The human DiGeorge syndrome critical region gene 8 and its D. melanogaster homolog are required for miRNA biogenesis. Curr. Biol. 14, 2162-2167 (2004).
50. Lee, Y. et al. The role of PACT in the RNA silencing pathway. EMBO J. 25, 522-532 (2006).
51. Fleige, S. & Pfaffl, M. W. RNA integrity and the effect on the real-time qRT-PCR performance. Mol. Aspects Med. 27, 126-139 (2006).
52. Sander, J. D. et al. ZiFiT (Zinc Finger Targeter): an updated zinc finger engineering tool. Nucleic Acids Res. 38, W462-W468 (2010).
53. Sander, J. D. et al. Targeted gene disruption in somatic zebrafish cells using engineered TALENs. Nat. Biotechnol. 29, 697-698 (2011).
54. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243-3248 (2001).